Biomarkers with greater sensitivity, specificity, and lead-time are needed to detect ovarian cancer at its early stage. Proteomic-based technology has the advantage of analyzing several proteins simultaneously. This technology can be applied to readily available samples such as blood or urine and allows data mining from a large input data base and overcomes the slow advances of one protein-one gene investigation.
Go to Previous Page
Go to Next Page